219 related articles for article (PubMed ID: 25340575)
1. Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign.
Diaz R; Luengo-Arratta SA; Seixas JD; Amata E; Devine W; Cordon-Obras C; Rojas-Barros DI; Jimenez E; Ortega F; Crouch S; Colmenarejo G; Fiandor JM; Martin JJ; Berlanga M; Gonzalez S; Manzano P; Navarro M; Pollastri MP
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3253. PubMed ID: 25340575
[TBL] [Abstract][Full Text] [Related]
2. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
Valenciano AL; Ramsey AC; Santos WL; Mackey ZB
Bioorg Med Chem; 2016 Oct; 24(19):4647-4651. PubMed ID: 27519462
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
Ferrigno F; Biancofiore I; Malancona S; Ponzi S; Paonessa G; Graziani R; Bresciani A; Gennari N; Di Marco A; Kaiser M; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3689-3692. PubMed ID: 30482621
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
[TBL] [Abstract][Full Text] [Related]
5. Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.
Volkov OA; Cosner CC; Brockway AJ; Kramer M; Booker M; Zhong S; Ketcherside A; Wei S; Longgood J; McCoy M; Richardson TE; Wring SA; Peel M; Klinger JD; Posner BA; De Brabander JK; Phillips MA
ACS Infect Dis; 2017 Jul; 3(7):512-526. PubMed ID: 28350440
[TBL] [Abstract][Full Text] [Related]
6. Indirubin Analogues Inhibit
Efstathiou A; Gaboriaud-Kolar N; Myrianthopoulos V; Vougogiannopoulou K; Subota I; Aicher S; Mikros E; Bastin P; Skaltsounis AL; Soteriadou K; Smirlis D
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910902
[TBL] [Abstract][Full Text] [Related]
7. From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.
Woodland A; Grimaldi R; Luksch T; Cleghorn LA; Ojo KK; Van Voorhis WC; Brenk R; Frearson JA; Gilbert IH; Wyatt PG
ChemMedChem; 2013 Jul; 8(7):1127-37. PubMed ID: 23776181
[TBL] [Abstract][Full Text] [Related]
8. Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.
Pham T; Walden M; Butler C; Diaz-Gonzalez R; Pérez-Moreno G; Ceballos-Pérez G; Gomez-Pérez V; García-Hernández R; Zecca H; Krakoff E; Kopec B; Ichire O; Mackenzie C; Pitot M; Ruiz LM; Gamarro F; González-Pacanowska D; Navarro M; Dounay AB
Bioorg Med Chem Lett; 2017 Aug; 27(16):3629-3635. PubMed ID: 28729055
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.
Cleghorn LA; Albrecht S; Stojanovski L; Simeons FR; Norval S; Kime R; Collie IT; De Rycker M; Campbell L; Hallyburton I; Frearson JA; Wyatt PG; Read KD; Gilbert IH
J Med Chem; 2015 Oct; 58(19):7695-706. PubMed ID: 26418485
[TBL] [Abstract][Full Text] [Related]
10. Whole-organism high-throughput screening against Trypanosoma brucei brucei.
Jones AJ; Avery VM
Expert Opin Drug Discov; 2013 May; 8(5):495-507. PubMed ID: 23540598
[TBL] [Abstract][Full Text] [Related]
11. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.
Sykes ML; Baell JB; Kaiser M; Chatelain E; Moawad SR; Ganame D; Ioset JR; Avery VM
PLoS Negl Trop Dis; 2012; 6(11):e1896. PubMed ID: 23209849
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided discovery of Trypanosoma brucei RNA-editing terminal uridylyl transferase 2 inhibitors.
Demir O; Labaied M; Merritt C; Stuart K; Amaro RE
Chem Biol Drug Des; 2014 Aug; 84(2):131-9. PubMed ID: 24903413
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening.
Pedró-Rosa L; Buckner FS; Ranade RM; Eberhart C; Madoux F; Gillespie JR; Koh CY; Brown S; Lohse J; Verlinde CL; Fan E; Bannister T; Scampavia L; Hol WG; Spicer T; Hodder P
J Biomol Screen; 2015 Jan; 20(1):122-30. PubMed ID: 25163684
[TBL] [Abstract][Full Text] [Related]
14. Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for
Singh B; Diaz-Gonzalez R; Ceballos-Perez G; Rojas-Barros DI; Gunaganti N; Gillingwater K; Martinez-Martinez MS; Manzano P; Navarro M; Pollastri MP
J Med Chem; 2020 Sep; 63(17):9912-9927. PubMed ID: 32786222
[TBL] [Abstract][Full Text] [Related]
15. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei.
Urbaniak MD; Mathieson T; Bantscheff M; Eberhard D; Grimaldi R; Miranda-Saavedra D; Wyatt P; Ferguson MA; Frearson J; Drewes G
ACS Chem Biol; 2012 Nov; 7(11):1858-65. PubMed ID: 22908928
[TBL] [Abstract][Full Text] [Related]
16. Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2017 Dec; 141():446-459. PubMed ID: 29049963
[TBL] [Abstract][Full Text] [Related]
17. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
Urbaniak MD; Tabudravu JN; Msaki A; Matera KM; Brenk R; Jaspars M; Ferguson MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5744-7. PubMed ID: 16962325
[TBL] [Abstract][Full Text] [Related]
19. Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics.
Klug DM; Tschiegg L; Diaz R; Rojas-Barros D; Perez-Moreno G; Ceballos G; García-Hernández R; Martinez-Martinez MS; Manzano P; Ruiz LM; Caffrey CR; Gamarro F; Pacanowska DG; Ferrins L; Navarro M; Pollastri MP
J Med Chem; 2020 Mar; 63(5):2527-2546. PubMed ID: 31670951
[TBL] [Abstract][Full Text] [Related]
20. From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis.
Devine WG; Diaz-Gonzalez R; Ceballos-Perez G; Rojas D; Satoh T; Tear W; Ranade RM; Barros-Álvarez X; Hol WG; Buckner FS; Navarro M; Pollastri MP
ACS Infect Dis; 2017 Mar; 3(3):225-236. PubMed ID: 28110521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
